A recent assessment by the World Health Organization (WHO) has highlighted that in India about 40% of the low-priced essential medicines are priced substantially higher than expected charges for production.While the high cost of latest and novel drugs for cancer, hepatitis C, and rare diseases are making it unaffordable for many patients, there are many commonly used drugs that is off patent for a long period used in the treatment of tuberculosis and malaria but are priced very high than the manufacturing cost. This has incr [...]